Selenium Deficiency and Thyroid Health: What the Evidence Shows

Selenium is a trace mineral obtained from food or supplements, not a drug. It is available in several chemical forms relevant to thyroid research: selenomethionine (an organic form found in food and most supplements), sodium selenite (an inorganic form used in some older trials), and selenium-enriched yeast (a mixture of organic selenium compounds). None of these is FDA-approved as a treatment for any thyroid disease. Where selenium is used clinically for thyroid conditions, it is a supplement used off-label, based on trial evidence and specialty-society statements rather than a drug label.

The direct answer

Selenium deficiency does not by itself cause overt hypothyroidism in most people, but it removes a necessary cofactor for thyroid hormone conversion and antioxidant defense, and low selenium status has been associated with higher thyroid antibody levels and higher TSH in observational research. Selenium supplementation has been studied most rigorously in Hashimoto's thyroiditis (antibody reduction) and mild Graves' orbitopathy (eye disease progression), with more limited and inconsistent evidence in subclinical hypothyroidism. Selenium testing and supplementation are reasonable to discuss with a physician for patients with autoimmune thyroid disease, malabsorption, or low-selenium geography, but they are not a substitute for standard thyroid hormone or antithyroid drug therapy, and should not be started without checking baseline selenium status given the narrow gap between adequate and excessive intake.

Why the thyroid depends on selenium

The thyroid gland concentrates selenium more than any other tissue in the body, because several of the enzymes that build and regulate thyroid hormone are selenoproteins, meaning selenium is built directly into their structure. Two enzyme families matter most for clinicians:

Deiodinases convert thyroxine (T4), the hormone the thyroid mainly secretes, into triiodothyronine (T3), the active hormone that tissues actually use. If selenium is not available to support deiodinase activity, T4-to-T3 conversion can fall even when total T4 looks normal on a standard panel, and a person can have symptoms consistent with low thyroid hormone action without an obviously abnormal TSH or T4.

Glutathione peroxidases neutralize hydrogen peroxide, a byproduct generated inside thyroid cells during normal hormone synthesis. Without adequate selenium, this oxidative byproduct accumulates, which is thought to contribute to thyroid tissue damage and to amplify autoimmune inflammation in conditions such as Hashimoto's thyroiditis. Recent narrative reviews of trace elements in autoimmune thyroid disease describe this oxidative and immune mechanism as one plausible pathway linking selenium status to disease activity, while noting that mechanistic plausibility does not by itself establish that supplementation changes clinical outcomes (review of trace elements in autoimmune thyroid disease, 2025).

Selenium requirements and thyroid vulnerability also vary across the life course. A 2025 review focused on selenium and thyroid health from fetal development through adolescence describes selenium as important for normal thyroid programming in pregnancy and childhood, and notes that both maternal and pediatric selenium status can influence thyroid outcomes in offspring (Thyroid Health and Selenium, 2025). This is relevant background for pregnant patients and families of young children, though it does not translate into a specific supplementation instruction without individualized evaluation.

Should you assume low selenium explains your symptoms?

Selenium deficiency is uncommon in people eating a varied diet in most high-income countries, because selenium content in food tracks selenium content in soil and many food supply chains mix grain and animal products from multiple regions. Deficiency is more plausible in a specific set of situations:

• Residence in a known low-selenium soil region (parts of central Europe, parts of China, some African regions, and reportedly parts of the UK, Scandinavia, and New Zealand relative to other regions)
• Malabsorptive conditions such as celiac disease, inflammatory bowel disease, or short bowel syndrome
• Long-term total parenteral nutrition
• A restrictive diet that avoids seafood, organ meats, and nuts

Outside these situations, a patient with hypothyroid symptoms and a normal, varied diet is unlikely to have selenium deficiency as the primary explanation, and standard thyroid function testing (TSH, free T4, and, where indicated, free T3 and TPO antibodies) should come first. Serum selenium testing is not part of routine thyroid panels in most health systems and is reasonable to add selectively rather than universally.

Should you take selenium if you have Hashimoto's thyroiditis?

Hashimoto's thyroiditis is an autoimmune condition marked by elevated thyroid peroxidase antibodies (TPO-Ab), lymphocytic infiltration of the thyroid, and gradual loss of thyroid function over years. It is among the most common autoimmune conditions worldwide.

Several randomized controlled trials, most using 200 mcg/day of selenomethionine or sodium selenite for 3 to 12 months, have reported reductions in TPO antibody titers compared with placebo, and a systematic review pooling multiple such trials found a consistent direction of effect. The exact magnitude of antibody reduction differs meaningfully between trials, and antibody reduction is a laboratory marker, not proof that patients feel better, need less levothyroxine, or avoid progression to overt hypothyroidism. Reported percentage reductions and confidence intervals vary between trials and have not been independently confirmed here, so they should not be treated as precise figures for an individual patient.

No major thyroid society currently recommends selenium supplementation for every patient with Hashimoto's thyroiditis. Where clinical guidance exists, it is generally framed as a discretionary option for selected patients rather than a standard of care, and it emphasizes that doses above 200 mcg/day are not established as more effective and carry more toxicity risk.

A decision framework for selenium and thyroid disease

This is not a substitute for individualized medical advice, but a structure for the conversation with a physician.

Step 1: What is the diagnosis?

• No thyroid disease, no symptoms: routine selenium supplementation is not supported by evidence and is not recommended. Meet the RDA through diet.
• Hashimoto's thyroiditis with elevated TPO-Ab: a supervised, time-limited trial of selenium may be reasonable if baseline selenium is low or borderline.
• Mild, active Graves' orbitopathy: selenium has the strongest trial support of any condition on this page, though confirmation of eligibility and dosing should come from an endocrinologist or ophthalmologist familiar with the trial protocols.
• Graves' hyperthyroidism without orbitopathy, or subclinical hypothyroidism: evidence is weaker and more mixed; selenium is not a substitute for standard monitoring or treatment.

Step 2: Check status before treating. Get a baseline serum or whole-blood selenium level. Supplementing without a baseline makes it impossible to judge whether a later blood level reflects deficiency correction or approaching the upper limit.

Step 3: If supplementing, set a stop rule in advance. A finite trial (commonly discussed as roughly 6 months) with a plan to recheck TPO-Ab and selenium level, and to stop if there is no antibody change or if selenium approaches the upper part of the normal range, avoids indefinite, unmonitored use.

Step 4: Know the exceptions that change the plan.

• Pregnancy or plans for pregnancy with known thyroid antibody positivity: selenium status may be more consequential here, but dosing must be supervised by an obstetric or endocrine clinician, not self-directed.
• Malabsorption or parenteral nutrition: baseline testing is more clearly justified regardless of thyroid diagnosis.
• Current use of statins, valproic acid, or cisplatin: these have been associated with lower selenium status in some reports and may be a reason to check a level, but this does not establish that supplementation is required or beneficial.

Step 5: Recognize what selenium will not do. It will not replace levothyroxine in overt hypothyroidism, will not replace antithyroid drugs in active Graves' hyperthyroidism, and has not been shown to reverse established autoimmune thyroid damage.

Should you take selenium for Graves' orbitopathy?

Graves' disease is the most common cause of hyperthyroidism in iodine-sufficient regions and is driven by antibodies that stimulate the TSH receptor. A meaningful proportion of patients develop Graves' orbitopathy, an inflammatory eye condition ranging from mild irritation to sight-threatening disease.

A European multicenter randomized, placebo-controlled trial in patients with mild, active Graves' orbitopathy found that selenium supplementation for about six months was associated with better eye-disease outcomes and less progression compared with placebo. This trial is one of the more frequently cited pieces of evidence in this area of endocrinology, and subsequent European specialist guidance has incorporated selenium as an option for mild orbitopathy. Reported response percentages for this trial vary somewhat between secondary sources and have not been independently confirmed here.

Selenium's role in Graves' hyperthyroidism itself, separate from the eye disease, is less settled. Selenium levels are often low at diagnosis and oxidative stress markers are elevated, which is consistent with selenium depletion being part of the disease process, but whether supplementation changes antibody trajectory or helps patients reach remission on antithyroid drugs is not established and remains an active research question.

Does selenium help subclinical hypothyroidism?

Subclinical hypothyroidism is a TSH above the reference range with a normal free T4. It is common, particularly in older women. Some small trials have reported that selenium supplementation in this group modestly lowers TSH and antibody titers over several months, and at least one cohort analysis has suggested that lower baseline selenium predicts a higher chance of progressing to overt hypothyroidism. These findings are worth discussing with a physician, but they come from a small number of trials and cohorts, effect sizes vary, and subclinical hypothyroidism management already depends heavily on symptom burden, antibody status, pregnancy planning, and cardiovascular risk factors independent of selenium. Selenium status is one input among several, not a stand-alone treatment decision.

How much selenium is safe, and from what source

The adult RDA for selenium is 55 mcg/day, rising to 60 mcg/day in pregnancy and 70 mcg/day while breastfeeding, according to the NIH Office of Dietary Supplements. The tolerable upper intake level is 400 mcg/day; chronic intake above this range is linked to selenosis, which can present as hair and nail changes, a garlic-like breath odor, gastrointestinal upset, and in severe cases neurologic or cardiac effects.

Food sources vary widely in selenium content depending on the selenium level of the soil where the food was grown or the animal was raised:

• Brazil nuts (selenium content varies substantially by growing region; a small number of nuts can meet or exceed the RDA)
• Tuna, sardines, and other seafood
• Organ meats such as beef kidney
• Eggs and sunflower seeds in smaller amounts

Selenomethionine, the organic form found naturally in food, is generally better absorbed than inorganic sodium selenite and is the form used in most recent thyroid trials. Selenium-enriched yeast behaves similarly to selenomethionine in most studies. Doses studied in thyroid research have most often been 200 mcg/day for Hashimoto's thyroiditis and Graves' orbitopathy trials, and lower doses (around 100 mcg/day) in some subclinical hypothyroidism trials, for defined periods rather than indefinitely.

The iodine-selenium interaction

Selenium and iodine work together in thyroid hormone metabolism, and correcting one without attention to the other can cause problems. In populations that are both iodine- and selenium-deficient, correcting selenium status without adequate iodine has, in some reported field observations, been associated with worsened thyroid outcomes rather than improvement. This interaction is a reason to think about both nutrients together rather than supplementing selenium in isolation, particularly in regions or patients with uncertain iodine status. This is an area where individualized clinical judgment, not a fixed rule, is appropriate.

Who should actually be tested

Serum or whole-blood selenium testing is not part of a standard thyroid panel and is reasonable to consider selectively rather than routinely, including for:

• Patients with confirmed Hashimoto's or Graves' disease who remain symptomatic despite optimized standard therapy
• Patients with malabsorptive gastrointestinal disease or on long-term parenteral nutrition
• Patients living in regions with reported low-selenium soils
• Pregnant patients with known thyroid antibody positivity, in coordination with their obstetric or endocrine clinician

A single selenium level, interpreted alongside a full thyroid panel (TSH, free T4, and TPO antibodies where relevant), can meaningfully inform whether selenium status is worth addressing or can be set aside as a factor.

What is established, what is plausible, and what is not established

Established: Selenium is a required cofactor for thyroid deiodinase and glutathione peroxidase enzymes; severe combined iodine and selenium deficiency is associated with more severe hypothyroid outcomes than iodine deficiency alone; chronic selenium intake above the tolerable upper limit causes selenosis.

Plausible but not settled: Selenium supplementation reduces TPO antibody titers in Hashimoto's thyroiditis over several months in people with elevated antibodies; selenium supplementation improves outcomes in mild, active Graves' orbitopathy over a defined treatment course; selenium status influences progression from subclinical to overt hypothyroidism in selenium-deficient individuals.

Not established: That selenium supplementation benefits people with normal selenium status and no autoimmune thyroid disease; that selenium supplementation changes hard outcomes such as need for levothyroxine, disease remission, or long-term antibody-driven organ damage; that selenium meaningfully alters the course of Graves' hyperthyroidism itself, separate from orbitopathy.

When to seek care rather than self-treat

Selenium supplementation should not be started as a substitute for evaluating new or worsening thyroid symptoms, unexplained weight change, palpitations, eye pain or vision change in a person with known Graves' disease, or symptoms of thyroid storm (high fever, rapid heart rate, agitation, confusion), which require urgent medical evaluation rather than a nutrition-based approach. Symptoms suggestive of selenosis, including hair loss, brittle nails, a persistent garlic-like breath odor, or neurologic symptoms in someone taking selenium supplements, should also prompt a call to a physician and stopping the supplement pending evaluation.